The GLP-1 Receptor: Why It Matters
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to food intake. It acts on GLP-1 receptors in the pancreas (stimulating insulin secretion), hypothalamus (suppressing appetite), stomach (slowing gastric emptying), and liver (suppressing glucagon). The native GLP-1 peptide has a plasma half-life of 1–2 minutes due to rapid DPP-4 enzyme degradation — making it impractical as a research or therapeutic molecule without modification.
How Semaglutide Extends Half-Life to ~7 Days
Semaglutide is a GLP-1 analog with two key structural modifications. First, a C18 fatty diacid chain is attached via a short linker to lysine at position 26. This chain enables reversible albumin binding in the bloodstream, which acts as a depot — the peptide slowly releases from albumin over time. Second, a substitution at position 8 (alanine → α-aminoisobutyric acid) blocks DPP-4 cleavage. Together, these changes extend the half-life from minutes to approximately 165 hours (~7 days), enabling once-weekly dosing in clinical use.
Central Appetite Suppression: The Weight Loss Mechanism
Beyond the pancreatic insulin effect, semaglutide crosses the blood-brain barrier at circumventricular organs (areas lacking a complete BBB) and activates GLP-1 receptors in the arcuate nucleus and brainstem. This drives central appetite suppression — reducing food intake not through nausea, but through modified satiety signaling. The STEP trials demonstrated 15–17% mean body weight loss at 2.4mg/week doses, primarily through reduced caloric intake rather than increased energy expenditure.
Documentation Standards for Semaglutide
Semaglutide is a 31-amino acid peptide (MW ~4,114 Da) with a fatty acid modification. HPLC analysis of modified peptides is more complex than unmodified ones — the fatty acid chain alters retention time and peak shape. Researchers should verify: (1) HPLC purity ≥98% with the correct modified peptide peak, (2) LC-MS/MS confirmation of the correct molecular weight including the fatty acid modification, (3) batch-specific lot number matching the vial, and (4) testing by a US-based ISO 17025 lab. Absence of MS identity confirmation for semaglutide is a significant red flag, as the fatty acid modification is what differentiates it from unmodified GLP-1 analogs.